Astragaloside IV Enhances Anti‐PD‐L1 Immunotherapy in Triple‐Negative Breast Cancer by Activating the cGAS‐STING Pathway
Drug Development Research · 2026
DOI: 10.1002/ddr.70311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Chuanchao Wei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Triterpenes, Saponins, Triple Negative Breast Neoplasms, Nucleotidyltransferases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China (NSFC), Project of the Science and Technology Commission of Minhang District, Shanghai.
Abstract (Originalsprache)
Astragaloside IV (AS‐IV), a natural compound from traditional Chinese medicine, has demonstrated anti‐tumor properties. This study aims to explore its potential to enhance anti‐mPD‐L1 immunotherapy in triple‐negative breast cancer (TNBC) by modulating the tumor immune microenvironment. Flow cytometry and immunofluorescence staining analyses were employed to evaluate the influence of AS‐IV on cell cycle distribution, apoptosis and DNA damage (phospho‐γH2AX staining). The antitumor effects of AS‐IV, anti‐mPD‐L1, or their combination were further investigated using a 4T1 murine breast cancer model. Immune cell infiltration within the tumor tissue was assessed by flow cytometry. AS‐IV significantly triggered apoptosis, G0‐G1 cell cycle arrest, as well as induced DNA damage and activation of the cGAS‐STING pathway in MDA‐MB‐231 and 4T1 cells. Interestingly, AS‐IV notably elevated PD‐L1 levels both in two TNBC cells. In vivo experiments indicated that AS‐IV treatment notably suppressed tumor growth and triggered tumor cell apoptosis. Meanwhile, AS‐IV enhanced anti‐tumor efficacy of anti‐mPD‐L1 on 4T1 murine model, as evidenced by increased infiltration of CD8⁺T cells and elevated secretion of IFN‐β, CCL5, and CXCL10. AS‐IV remodeled the tumor immune microenvironment and induced PD‐L1 upregulation, thereby potentiating the efficacy of anti‐mPD‐L1 immunotherapy. These findings suggest that AS‐IV may serve as a promising immunomodulatory adjuvant in cancer immunotherapy for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai, China.
- Department of Ophthalmology, Quzhou TCM Hospital at the Junction of Four Provinces Affiliated to Zhejiang Chinese Medical University, Quzhou, China.
ORCID-Profile: Hongchang Li
Förderung
- National Natural Science Foundation of China (NSFC)
- Project of the Science and Technology Commission of Minhang District, Shanghai
Zitieren
APA
Wei, C., Zhang, Q., Mao, A., Pan, G., Liu, J., Fan, X., & Li, H. (2026). Astragaloside IV Enhances Anti‐PD‐L1 Immunotherapy in Triple‐Negative Breast Cancer by Activating the cGAS‐STING Pathway. Drug Development Research. https://doi.org/10.1002/ddr.70311
Vancouver
Wei C, Zhang Q, Mao A, Pan G, Liu J, Fan X, et al. Astragaloside IV Enhances Anti‐PD‐L1 Immunotherapy in Triple‐Negative Breast Cancer by Activating the cGAS‐STING Pathway. Drug Development Research. 2026. doi:10.1002/ddr.70311
BibTeX
@article{Wei2026,
author = {Wei, Chuanchao and Zhang, Qing and Mao, Anwei and Pan, Gaofeng and Liu, Jiazhe and Fan, Xinjuan and Li, Hongchang},
title = {Astragaloside IV Enhances Anti‐PD‐L1 Immunotherapy in Triple‐Negative Breast Cancer by Activating the cGAS‐STING Pathway},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70311}
}
EUVIMED